Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simlukafusp alfa + Atezolizumab +/- Bevacizumab in Advanced RCC
NCT03063762Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2017
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of simlukafusp alfa in renal cell carcinoma (RCC) (4 arms), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities, Maximum Tolerated Dose and 1 more. Started Mar 2017; status: completed.
02
Drugs
simlukafusp alfa
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03063762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063762.